1. Serum HBV pgRNA as a clinical marker for cccDNA activity
Katja Giersch, Lena Allweiss, Tassilo Volz, Maura Dandri, Marc Lütgehetmann 
Journal of Hepatology 
Volume 66, Issue 2, Pages (February 2017)
DOI: /j.jhep
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Serum HBV pgRNA as a clinical marker for cccDNA activity. (A and B) Serum HBV DNA (grey) and HBV pgRNA (black) levels in humanized mice before (baseline) and after treatment with NUCs (A, n=5) or PegIFNα (B, n=4) for 4–6weeks. Each mouse is depicted with total median and range. Every symbol represents one mouse. (C) Correlation of serum pgRNA and intrahepatic pgRNA relative to human GAPDH in HBV-infected mice untreated (n=23, black dots) and treated with NUCs (n=5, white dots) or PegIFNα (n=10, grey dots). Black line: Spearman r=0.82, p< (D) Correlation of serum pgRNA and intrahepatic cccDNA/human cell in HBV-infected mice untreated (n=23, black dots and black solid line; spearman r=0.89, p<0.0001) or treated with PegIFNα for 2–6weeks (n=10, grey dots and grey line; spearman r=0.13, p=0.7330).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2016 European Association for the Study of the Liver Terms and Conditions